Eficácia e segurança do uso de imunobiológicos no tratamento de espondilite anquilosante e sua relação com a qualidade de vida dos pacientes acompanhados no Hospital Universitário Lauro Wanderley (HULW-UFPB)

Abstract

Ankylosing spondylitis (AS) is an immune-mediated, inflammatory and systemic arthropathy, which often leads to impaired quality of life and functional impairment of its carriers. First-line treatment remains the use of non-hormonal anti-inflammatory drugs, but in patients who are intolerant or who do not respond to this treatment, immunobiologicals can be used. Currently, biological drugs are widely used to treat various rheumatic diseases, including AS. However, therapy with immunobiologicals is not risk-free and has adverse effects such as infusion reactions, increased risk of opportunistic infections and hypersensitivity reactions. This study aims to outline the clinical, laboratory and epidemiological profile of patients with AS undergoing treatment with immunobiological drugs followed up at the rheumatology outpatient clinic of Hospital Universitário Lauro Wanderley - UFPB, evaluating the efficacy, safety and its impacts in quality of life on this group of patients. This is an observational, cross-sectional study, of a quantitative nature, which will be conducted through the application of data collection instruments developed specifically for the study, and questionnaires already validated to assess quality of life and disease activity in patients with AS, with subsequent statistical analysis and discussion of the results obtained. The project seeks to improve knowledge about this therapeutic resource, opening possibilities to strengthen adherence to treatment, reduce and prevent its adverse effects and collaborate to a better prognosis with a consequent improvement in quality of life.